Vulvar Cancer Market to Grow with a CAGR of 6.20% through 2028
Increase in the incidence of Vulvar Cancer and
increase advances in genetic profiling and personalized treatment is expected
to drive the Global Vulvar Cancer Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Vulvar
Cancer Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2028”, the Global Vulvar Cancer Market stood at USD 548.30
billion in 2022 and is anticipated to grow with a CAGR of 6.20% in the forecast
period, 2024-2028. The awareness among individuals regarding Vulvar Cancer has
led to favorable market conditions for the global Vulvar Cancer market. Several
factors contribute to the growth of various Vulvar Cancer products.
The global population continues to age, the likelihood
of developing vulvar cancer rises. This is mainly because vulvar cancer is more
frequently diagnosed in older women. The shift toward an older demographic
contributes to the increasing incidence rates observed in recent years. With
the aging population comes a larger pool of individuals who are susceptible to
this disease. It is crucial to comprehend the various risk factors associated
with vulvar cancer. Beyond lifestyle choices and age, several factors can
heighten the vulnerability to this condition. Chronic inflammatory skin
conditions, like lichen sclerosus, can predispose individuals to vulvar cancer.
Additionally, infection with specific strains of human papillomavirus (HPV) has
been linked to an elevated risk of developing vulvar cancer.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Vulvar
Cancer Market.”
Researchers are continually investigating novel drug
compounds and treatment protocols for vulvar cancer. Clinical trials play a
vital role in assessing the effectiveness and safety of these fresh treatment
approaches. Recent breakthroughs encompass immunotherapy alternatives and
precisely targeted therapies designed for specific genetic mutations detected
in vulvar cancer. The age of personalized medicine has dawned, and this extends
to the treatment of vulvar cancer. Tumor genetic profiling enables oncologists
to customize treatment strategies for each patient, enhancing the chances of
success while minimizing potential side effects, which will further fuel market
growth.
In September 2023, Merck Announces Results from Phase
3 KEYNOTE-189 Trial Showing KEYTRUDA® (Pembrolizumab) Significantly Improved
Overall Survival (OS) Compared to Chemotherapy in Patients With Previously
Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC).
The adoption of unhealthy lifestyles, including
smoking and poor dietary habits, has contributed significantly to the surge in
vulvar cancer cases. These choices can lead to obesity, which is a
well-established risk factor for vulvar cancer. Moreover, the prevalence of
sexually transmitted infections (STIs) among individuals engaging in risky
sexual behaviors has also played a role in driving up incidence rates.
In today's fast-paced world, Vulvar cancer can cause
physical pain, discomfort, and distress for patients. The diagnosis and
treatment process often involves surgery, radiation therapy, chemotherapy, or a
combination of these, leading to side effects such as pain, fatigue, nausea, and
emotional distress. These physical and emotional challenges can significantly
affect a patient's quality of life and ability to keep pace with their daily
routines. For individuals diagnosed with vulvar cancer, treatment and recovery
may necessitate taking time off work or reducing work hours. This can have a
direct impact on their career and financial stability. Additionally, the
physical and emotional toll of the disease can reduce productivity, affecting
work performance. The cost of vulvar cancer treatment, including medical bills,
medication, and follow-up care, can be substantial. In many cases, patients and
their families face financial burdens, which can lead to stress and anxiety.
Coping with these financial challenges in a fast-paced world can be
particularly daunting. Vulvar cancer and its treatment may result in long-term
effects on a patient's quality of life. This can include sexual dysfunction,
changes in body image, and psychological distress. In a world that often
emphasizes physical appearance and sexual performance, these changes can be
particularly challenging to navigate. The fast-paced lifestyle of modern
society also affects caregivers. Family members or friends who provide support
to vulvar cancer patients may experience stress, fatigue, and emotional strain
as they juggle their caregiving responsibilities with work, personal life, and
other commitments.
The growing awareness among consumers regarding health
and wellness has shifted the focus towards the ideology of "prevention is
better than cure." As a result, more individuals are relying on
nutraceuticals, functional foods, and dietary and Vulvar Cancer to lead a
healthy and disease-free life.
In recent times, Human papillomavirus (HPV) is a major
risk factor for vulvar cancer. HPV vaccines, such as Gardasil and Cervarix,
have been developed to protect against the most common high-risk HPV strains
(HPV-16 and HPV-18). These vaccines are recommended for both males and females
and are typically administered during adolescence. Getting vaccinated is a
crucial preventive measure. Practicing safe sex by using condoms or dental dams
can reduce the risk of HPV transmission. Limiting the number of sexual partners
and having a mutually monogamous relationship can also lower the risk. Maintaining
good genital hygiene is important. Avoid using harsh soaps, douches, or
feminine hygiene products that can irritate the vulva. Keeping the genital area
clean and dry can help prevent skin conditions that may contribute to vulvar
cancer. Smoking is a known risk factor for vulvar cancer. Quitting smoking can
significantly reduce the risk not only for vulvar cancer but for several other
cancers and health conditions as well. However, Limited Awareness and Early
Detection may hinder market growth. Moreover, challenges related to Research
Funding and Innovation and Limited Access to Specialized Care may pose
obstacles to the Vulvar Cancer market in the near future.
The Global Vulvar Cancer Market is segmented into cancer
type, treatment type, end-user, regional distribution, and company.
Based on its cancer type, the Vulvar Squamous Cell
Carcinoma is the most common type of vulvar cancer, representing approximately
90% of all cases. Its high incidence rates contribute significantly to its
dominance within the Global Vulvar Cancer Market. This prevalence can be attributed
to various risk factors, including age, HPV infection, smoking, and chronic
vulvar skin conditions. Efforts to detect vulvar cancer at an early, treatable
stage have largely focused on Vulvar Squamous Cell Carcinoma due to its
frequency. Routine gynecological examinations and screening programs often
prioritize the detection of squamous cell carcinomas. Early diagnosis can lead
to less invasive treatment options and better prognoses, making VSCC a central
concern for healthcare professionals. The dominance of Vulvar Squamous Cell
Carcinoma has also been influenced by the significant progress made in its
treatment. Researchers have developed targeted therapies and immunotherapies
specifically tailored to combat squamous cell carcinomas.
Based on region, North America segment is expected to
grow during the forecast period. North America boasts a robust
healthcare infrastructure with state-of-the-art hospitals, clinics, and cancer
centers. These facilities offer a wide range of diagnostic, treatment, and
support services, making them central in the fight against vulvar cancer.The
region is at the forefront of medical technology and innovation. Advanced
diagnostic tools, surgical techniques, and treatment modalities are readily
available, allowing for early detection and effective management of vulvar
cancer. North American institutions actively engage in vulvar cancer research
and clinical trials. This research contributes to the development of novel
treatments, targeted therapies, and personalized medicine approaches for vulvar
cancer patients. The region places significant emphasis on public health
awareness campaigns. This has led to higher rates of early detection and
patient engagement, resulting in better treatment outcomes.
The Asia-Pacific market is poised to be the
fastest-growing market, offering lucrative growth opportunities for Vulvar
Cancer players during the forecast period. Factors such as the APAC region is
home to a large and aging population. As the population ages, the incidence of
vulvar cancer is expected to rise, contributing to increased demand for
healthcare services. Many APAC countries have been investing in their
healthcare infrastructure. This includes the expansion of cancer treatment
facilities, the adoption of advanced medical technologies, and the enhancement
of healthcare delivery systems. Awareness about vulvar cancer and the
importance of early detection is on the rise in the APAC region.
Major companies operating in Global Vulvar Cancer Market
are:
- Merck & Co. Inc.
- Sanofi SA
- Novartis AG
- Astellas Pharma Inc.
- Pfizer Inc.
- Abbott Laboratories
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Advancements in Treatment and increasing Investments
in Healthcare Infrastructure are key drivers of the Vulvar Cancer market. In
recent years, the growing Ongoing research in immunotherapy, including the
development of new immune checkpoint inhibitors, holds promise for more
effective vulvar cancer treatments. Moreover, the growing consumer emphasis on
preventative healthcare products has enhanced production and marketing efforts.
To meet the demands of the market, manufacturers are increasingly incorporating
cutting-edge technologies with high production efficiency. Rising consumer
acceptance and continuous product innovation will further ensure the growth of
the Vulvar Cancer and supplements market in the coming years.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Vulvar Cancer Market – Global Industry Size, Share,
Trends, Opportunity, & Forecast 2018-2028 Segmented By Cancer Type (Vulvar
Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell
Carcinoma), By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision,
Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic
Therapy), By End-User (Hospitals & Clinics, Research & Academic
Institutes, Others), By Region, Competition”, has evaluated the future growth
potential of Global Vulvar Cancer Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Vulvar Cancer Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com